Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
Iressa (Gefitinib) is an orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) involved in cell signal transduction processes critical to proliferation, apoptosis, repair, and angiogenesis of cancer cells. [11C]Iressa was first designed and synthesized as a new potential positron emission tomography (PET) cancer imaging agent for EGFR-TK in 30-40% radiochemical yield with 4.0-6.0 Ci/micromol specific activity at end of bombardment (EOB).
Wang
Ji-Quan
JQ
Department of Radiology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Gao
Mingzhang
M
Miller
Kathy D
KD
Sledge
George W
GW
Zheng
Qi-Huang
QH
D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000077156:Gefitinib; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis* / Q000201:enzymology; D049268:Positron-Emission Tomography; D011799:Quinazolines / Q000138:chemical synthesis* / Q000494:pharmacology
D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib